Sun Pharma Advanced Research Company Share Price Target 2026 Analyst Forecast Bull and Bear Case

The Sun Pharma Advanced Research Company share price target, currently trading near its 52-week high of Rs 253, stands at Rs 280 for 2026, implying approximately 18% upside from the current market price of Rs 238. The stock trades at a price-to-earnings ratio of 4.90x, reflecting attractive value versus sector peers, with a market capitalisation of Rs 7,613 Cr. Investors tracking the pharmaceuticals segment are closely watching Sun Pharma Advanced Research Company as an emerging opportunity given its 52-week range of Rs 108 to Rs 253. This analysis covers the bull case, bear case, and key catalysts that will define the Sun Pharma Advanced Research Company share price target trajectory through 2026.

Click Here – Get Free Investment Predictions

Sun Pharma Advanced Research Company Company Overview and Key Metrics

Sun Pharma Advanced Research Company	Details
NSE Symbol	SPARC
Sector	Pharmaceuticals
CMP (Rs)	238
52W High (Rs)	253
52W Low (Rs)	108
Market Cap (Rs Cr)	7,613 Cr
P/E Ratio	4.90
12M Target (Rs)	280
Bull Case (Rs)	320
Bear Case (Rs)	215

Sun Pharma Advanced Research Company is a pharmaceuticals company listed on the National Stock Exchange (NSE: SPARC). With a market capitalisation of Rs 7,613 Cr, the company occupies a defined position in the Indian pharmaceuticals landscape. The stock has traded in a wide range over the past 12 months, touching a high of Rs 253 and a low of Rs 108, before arriving at its current level of Rs 238. Uniresearch analysts project a 12-month Sun Pharma Advanced Research Company share price target of Rs 280, with a bull case of Rs 320 and a bear case of Rs 215.

Why Is the Sun Pharma Advanced Research Company share price target Set at Rs 280 for 2026

FY27 Earnings Delivery and Revenue Acceleration

The Sun Pharma Advanced Research Company share price target of Rs 280 is anchored in expectations of FY27 earnings delivery. At a P/E of 4.90x on trailing earnings, the stock is attractively valued. Consistent revenue growth and margin improvement in coming quarters can re-rate the stock towards the Rs 280 target.

Domestic Formulations Growth and NLEM Coverage

India’s pharma market is expanding at 10-12% annually driven by rising health awareness and increasing prescription volumes. Companies with a strong domestic branded generic presence are well-positioned to capture this structural demand growth.

USFDA and Export Approvals Pipeline

Pharma companies that successfully navigate USFDA inspections and build a credible ANDA pipeline can see significant margin expansion through regulated market sales. Export realizations are typically three to five times domestic pricing.

RBI Rate Cut Cycle and Lower Cost of Capital

The Reserve Bank of India has shifted to an accommodative monetary policy stance, with rate cuts reducing borrowing costs across the economy. For Sun Pharma Advanced Research Company, lower interest rates translate to reduced finance costs and potentially higher consumer demand in its end markets, creating a favourable backdrop for the Sun Pharma Advanced Research Company share price target to materialise by year-end.

Union Budget 2026 and Policy Tailwinds

The Union Budget 2026-27 has maintained strong capex allocation of Rs 11 lakh crore for infrastructure, directly benefiting sectors including pharmaceuticals. Tax rationalisation and sector-specific policy support create a constructive policy environment that supports the Sun Pharma Advanced Research Company share price target thesis through improved demand visibility.

Sun Pharma Advanced Research Company Share Price Target Short Term, 12 Month and Long Term

Short Term Sun Pharma Advanced Research Company Share Price Target: 3 to 6 Months

In the near term, the Sun Pharma Advanced Research Company share price target for the next 3 to 6 months is pegged at Rs 255, contingent on Q1 FY27 earnings meeting expectations and sustained buying interest in the pharmaceuticals segment. Technically, the stock needs to hold the Rs 113-119 zone for this short-term target to remain valid.

12 Month Sun Pharma Advanced Research Company Share Price Target 2026

Our 12-month Sun Pharma Advanced Research Company share price target is Rs 280. This target is based on the Uniresearch fundamental estimate, which factors in FY27 revenue growth, margin normalisation, and sector re-rating potential. The Rs 280 level represents approximately 18% upside from the current price of Rs 238.

Long Term Sun Pharma Advanced Research Company Share Price Target: FY27 to FY28

Over a 2 to 3 year horizon, the long-term Sun Pharma Advanced Research Company share price target is estimated between Rs 322 and Rs 378, assuming continued compounding in earnings, potential capacity expansions, and improved market positioning. Investors with a multi-year holding perspective may find the current CMP of Rs 238 an attractive accumulation level.

Bull Case and Bear Case for Sun Pharma Advanced Research Company Share Price Target

Bull Case: Rs 320

In the bull case scenario, Sun Pharma Advanced Research Company delivers above-estimate earnings growth driven by strong demand, margin expansion, and new business wins. If these catalysts materialise simultaneously, the Sun Pharma Advanced Research Company share price target could reach Rs 320, implying approximately 34% upside from the current market price.

Bear Case: Rs 215

The bear case of Rs 215 assumes earnings disappointment, sector-level de-rating, or broader market selloff driven by FII outflows. In this scenario, Sun Pharma Advanced Research Company could re-test support levels closer to its 52-week low of Rs 108, representing a downside risk investors should monitor.

Scenario	Target Price (Rs)	Upside/Downside from CMP	Key Assumption
Bull Case	320	34%	Strong earnings growth, sector re-rating
Base Case	280	18%	Steady earnings, margin improvement
Bear Case	215	-10%	Earnings miss, macro headwinds

Key Risks to the Sun Pharma Advanced Research Company Share Price Target 2026

Macro Headwind from Global Slowdown and US Tariff Policy

A sharper-than-expected global slowdown or escalation in US-China trade tensions could dampen demand across sectors. Sun Pharma Advanced Research Company faces indirect risk if its customers or supply chain partners are impacted by slower global growth, as this could translate to lower order volumes or pricing pressure.

Valuation Risk and Earnings Miss Scenario

If Sun Pharma Advanced Research Company reports quarterly earnings below analyst estimates or provides weak forward guidance, the stock could see significant de-rating. Elevated valuations in some segments leave limited margin for error, making execution risk a critical near-term concern.

Competitive Pressure in the Pharmaceuticals Segment

The pharmaceuticals space in India is increasingly competitive with both domestic players and global companies vying for market share. Price competition, product commoditisation, or loss of key client contracts could pressure Sun Pharma Advanced Research Company’s revenue trajectory.

FII Selling and Broader Market Volatility

Foreign Institutional Investor selling in Indian equities has historically led to broad-based price corrections even in fundamentally sound companies. Sun Pharma Advanced Research Company’s share price could face near-term pressure if FII sentiment turns risk-off due to global monetary policy changes.

How to Invest in Sun Pharma Advanced Research Company Stock

Step 1: Research and Fundamental Analysis. Before investing, thoroughly review Sun Pharma Advanced Research Company’s quarterly results, annual report, and management commentary. Focus on revenue growth trajectory, operating margin trends, and debt levels to assess whether the Sun Pharma Advanced Research Company share price target of Rs 280 is achievable.

Step 2: Use Stock Screeners for Live Data.

Check Sun Pharma Advanced Research Company Live Data on Univest Screener

Monitor key metrics including P/E, return on equity, and promoter holding changes. These ratios can confirm or challenge the Sun Pharma Advanced Research Company share price target thesis in real time.

Step 3: Define Your Entry Zone. The current CMP of Rs 238 is within the identified accumulation zone based on the 52-week low of Rs 108 and the Uniresearch target of Rs 280. Consider entering in tranches to average your cost over market fluctuations.

Step 4: Set Stop Loss and Risk Management Levels. Always define a stop-loss level before investing. A prudent stop-loss for Sun Pharma Advanced Research Company based on the current technical setup would be in the Rs 209 to Rs 219 range. Never risk more than 2-5% of your portfolio in any single position.

Step 5: Open a Zero-Brokerage Demat Account. To invest in Sun Pharma Advanced Research Company at zero brokerage, open your demat account with Univest, which combines SEBI-registered research with integrated trading. This allows you to act on the Sun Pharma Advanced Research Company share price target analysis without incurring unnecessary transaction costs.

Download the Univest iOS App or Univest Android App to track Sun Pharma Advanced Research Company live price and get daily stock recommendations.

Conclusion

The Sun Pharma Advanced Research Company share price target for 2026 is Rs 280, with a bull case of Rs 320 and a bear case of Rs 215, based on Uniresearch estimates as of 29 June 2026. At a CMP of Rs 238 with a 52-week range of Rs 108 to Rs 253, Sun Pharma Advanced Research Company presents a risk-reward opportunity that warrants monitoring. Investors should review Q1 FY27 results, track management commentary on guidance, and consult a SEBI-registered advisor before making investment decisions. The Sun Pharma Advanced Research Company share price target outlined here is for educational purposes only.

FAQs on Sun Pharma Advanced Research Company Share Price Target 2026

What is the Sun Pharma Advanced Research Company share price target for 2026?

Ans. The Sun Pharma Advanced Research Company share price target for 2026, as per Uniresearch estimate, is Rs 280. This implies approximately 18% upside from the current market price of Rs 238.

Is Sun Pharma Advanced Research Company a good stock to buy right now?

Ans. Whether Sun Pharma Advanced Research Company is a good buy depends on your investment horizon, risk appetite, and portfolio allocation. The Uniresearch Sun Pharma Advanced Research Company share price target of Rs 280 implies meaningful upside, but investors must assess company fundamentals and market conditions before investing.

What is Sun Pharma Advanced Research Company’s 52-week high and low?

Ans. Sun Pharma Advanced Research Company’s 52-week high is Rs 253 and the 52-week low is Rs 108, as of 29 June 2026. The current price of Rs 238 represents a 120% gain from the 52-week low.

What is the market cap of Sun Pharma Advanced Research Company?

Ans. The market capitalisation of Sun Pharma Advanced Research Company is approximately Rs 7,613 Cr, as of 29 June 2026.

What are the key risks to the Sun Pharma Advanced Research Company share price target?

Ans. Key risks to the Sun Pharma Advanced Research Company share price target of Rs 280 include earnings disappointment, global macro headwinds, FII selling pressure, and competitive intensity in the pharmaceuticals sector. Any of these factors could delay or reduce the target realisation.

What is the bull case target for Sun Pharma Advanced Research Company in 2026?

Ans. In the bull case scenario, the Sun Pharma Advanced Research Company share price target could reach Rs 320, implying approximately 34% upside from the current level. This assumes stronger-than-expected earnings growth and sector re-rating.

Where can I track Sun Pharma Advanced Research Company share price live?

Ans. You can track Sun Pharma Advanced Research Company (NSE: SPARC) live price, charts, and fundamental data on the Univest app or screener. The Univest platform provides real-time price data, analyst research, and portfolio tracking in one place.

How do I invest in Sun Pharma Advanced Research Company stock?

Ans. To invest in Sun Pharma Advanced Research Company, open a demat account with a SEBI-registered broker like Univest, which offers zero brokerage and integrated research. Search for the ticker SPARC on NSE, review fundamentals using the Univest Screener, and invest based on your financial goals and risk profile.